If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email email@example.com.
Please tell us what format you need. It will help us if you say what assistive technology you use.
Lynne Featherstone writes to the chair of the ACMD regarding the ongoing review of the generic definitions used in the Misuse of Drugs Act 1971 and its latest advice to update drug controls on synthetic cannabinoids.